All News
Featured Abstracts from Industry at EULAR 2021
Many great presentations this week at EULAR 2021 will feature industry sponsored clinical trials and reports. Often these become the pivotal studies for regulatory approval and the annual congresses are their first look.
Read Article
Efficacy of 6 Weeks Antibiotics with Prosthetic Joint Infections
The NEJM has published the results of a French multicenter study showing that prosthetic joint infections can be successfully managed with 6 weeks of antibiotic therapy; this was noninferior and had better outcomes compared to 12 weeks of antibiotic therapy.
Read Article
Congress Slams AbbVie Over Price Hikes, 'Frivolous' Patents
MedPage Today
House lawmakers on both sides of the aisle pummeled AbbVie CEO Richard Gonzalez for raising the price of two widely used drugs and for the company's "legally questionable" tactics to head off competition from biosimilars, despite pulling in healthy profits.
Read Article
RheumNow Podcast – Myth Busters (5.21.2021)
Dr Jack Cush reviews the news and journal reports from the past week on RheumNow.com
Read Article
#Eular2021 "Just because they do not have nonradiographic-AxSpa, it does not mean that the disease burden is less (compared to radiographic-AxSpa)!" Dr. Atul Deodhar @RheumNow
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Crosssectional multicentre study clusters phenotypes of #spondyloarthritis differentiating two types: axial and peripheral, Fitted well to either diagnoses of ax-SpA or #PsA. Still overlap of features like arthritis, dactylitis and enthesitis exists. #OP0047 #EULAR2021 @RheumNow https://t.co/sru9bT4mla
Paul Studenic Stiddyo ( View Tweet)
#Eular2021: Is AS & nr-AxSpA the same disease? The current consensus is that they are the two ends of the spectrum -- same disease! @RheumNow https://t.co/r0fTtp3Uip
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
#EULAR2021 M:F ratio in nr-AxSpa is 1:1. The baseline features between r-AxSpa and nr-AxSpA is similar with equal burden of disease. @RheumNow https://t.co/tm9Y6OB5TY
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Comparison of disease activity and PROs in AxSpA vs. AxPsA
⭐️AxSpA ⬆️ uveitis and IBD
⭐️AxPsA ⬆️enthesitis and dactylitis
⭐️AxSpA pts ⬆️pain, spinal pain PROs
⭐️Fatigue and work impairment did not differ in AxSpA vs AxPsA
Abs#OP0049 #EULAR2021 @RheumNow https://t.co/wGD6IA5ahb
Robert B Chao, MD doctorRBC ( View Tweet)
Secukinumab effective in AS patients, irrespective of gender
AQUILA 52 week study
⭐️improvement in BASDAI, PGA, severity of depressive mood in both men and women
⭐️women had overall higher disease burden in global functioning and depressive mood
POS0899
#EULAR2021 @RheumNow
Robert B Chao, MD doctorRBC ( View Tweet)
C-VIEW Study: Certolizumab reduced Anterior Uveitis flares in AxSpA
⭐️82% ⬇️ in uveitis flare event
⭐️reduction in axSpA disease activity
⭐️no new safety signals
POS0897 #EULAR2021 @RheumNow https://t.co/182iHfkSTY
Robert B Chao, MD doctorRBC ( View Tweet)
Quick update from #EULAR2021! Patient reported outcomes are important but how can we use them clinically in a meaningful way. Some key SpA/PsA findings from the experts at ASRI and the CorEvitas registry @rheumnow https://t.co/irxQs7Yzrx
Dr. Rachel Tate uptoTate ( View Tweet)
In DESIR AxSpA cohort: only 25% of patients achieved remission at 5 year follow up!!! Lower SES and ^ weight were negative factors in remission. Abstract #OP0052 #EULAR2021 @RheumNow https://t.co/X4wN1wIGfX https://t.co/DKBIXmEmki
Dr. Rachel Tate uptoTate ( View Tweet)
Female AxSpA pts report worse PROs but have better spinal mobility vs male AxSpA pts. Dz activity pattern similar in 4/6 BASDAI components regardless of gender. Females reports ^ fatigue, males report ^ spinal pain. Abstract# OP0051 #EULAR2021 @RheumNow https://t.co/U8T8JEWwCp https://t.co/yNP6PuA8PD
Dr. Rachel Tate uptoTate ( View Tweet)
Differences in PROs found in CORRONA(now CorEvitas) PsA/SpA registry Ax-PsA and AxSpA patients. Can we better use PROs for disease characterization/differentiation? Abstract #OP0049 #EULAR2021 @RheumNow https://t.co/uHW2FQe0A5 https://t.co/HuPPUTAC9Z
Dr. Rachel Tate uptoTate ( View Tweet)
Does it matter if you diagnose a symptomatic pt w/ nr-axSpA vs r-axSpA? (2/2) Interestingly there are smaller deltas between ASAS40 results in PBO vs nr-axSpA compared to axSpA vs PBO in MEASURE 2, PREVENT, COAST-V, COAST-X, RAPID, C-axSpAnd. Dr. Deodhar #EULAR2021 @RheumNow https://t.co/V8zlZdGltQ
Dr. Rachel Tate uptoTate ( View Tweet)
Does it matter if you diagnose a symptomatic patient with nr-axSpA vs radiographic axSpA? (1/2)Dr. Deodhar discusses differences in tx withdrawal/dose reduction(PBO) shown in RE-EMBARK, ABILITY-3, C-OPTIMISE. #EULAR2021 @RheumNow https://t.co/wVYsPYFLAi
Dr. Rachel Tate uptoTate ( View Tweet)
Dr. Deodhar reviews ASAS imaging/clinical classification and defines nrAxSpA at #EULAR2021 @RheumNow https://t.co/OdlQvGyNfY
Dr. Rachel Tate uptoTate ( View Tweet)
RNL 2021: Treatment Advances in SpA: Dr. Nigil Haroon
Dr. Nigil Haroon presents Treatment Advances in SpA at RheumNow Live 2021.
https://t.co/9ZA0loThx6
Links:
Dr. John Cush RheumNow ( View Tweet)
News: Factors Associated with COVID-19 Deaths in Rheumatic Patients
https://t.co/FzsINtpZEz https://t.co/QzuLZRKaZy
Links:
Dr. John Cush RheumNow ( View Tweet)
